R
Raymonde Busch
Researcher at Technische Universität München
Publications - 245
Citations - 22048
Raymonde Busch is an academic researcher from Technische Universität München. The author has contributed to research in topics: Chronic lymphocytic leukemia & Fludarabine. The author has an hindex of 70, co-authored 245 publications receiving 20829 citations. Previous affiliations of Raymonde Busch include Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek,Kirsten Fischer,Günter Fingerle-Rowson,Anna-Maria Fink,Raymonde Busch,Jiří Mayer,Manfred Hensel,Georg Hopfinger,G D Hess,U. Von Grünhagen,Matthias Bergmann,John Catalano,Pier Luigi Zinzani,Federico Caligaris-Cappio,John F. Seymour,Alain Berrebi,Ulrich Jäger,Bruno Cazin,Marek Trneny,Anne Westermann,Clemens M. Wendtner,Barbara Eichhorst,Peter Staib,Andreas Bühler,Dirk Winkler,Thorsten Zenz,S Böttcher,Matthias Ritgen,Myriam Mendila,Michael Kneba,Hartmut Döhner,Stephan Stilgenbauer +31 more
TL;DR: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.
Journal ArticleDOI
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede,Kirsten Fischer,Raymonde Busch,Anja Engelke,Barbara Eichhorst,Clemens M. Wendtner,Tatiana Chagorova,Javier de la Serna,Marie-Sarah Dilhuydy,Thomas Illmer,Stephen Opat,Carolyn Owen,Olga Samoylova,Karl-Anton Kreuzer,Stephan Stilgenbauer,Hartmut Döhner,Anton W. Langerak,Matthias Ritgen,Michael Kneba,Elina Asikanius,Kathryn Humphrey,Michael Wenger,Michael Hallek +22 more
TL;DR: Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions, and obinutuzumab was superior to rituximab when each was combined with chlorambucil.
Journal ArticleDOI
Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging
Wolfgang A. Weber,Katja Ott,Karen Becker,H. J. Dittler,Hermann Helmberger,Norbert Avril,G. Meisetschläger,Raymonde Busch,J. R. Siewert,Markus Schwaiger,Ulrich Fink +10 more
TL;DR: PET imaging may differentiate responding and nonresponding tumors early in the course of therapy by avoiding ineffective and potentially harmful treatment, this may markedly facilitate the use of preoperative therapy, especially in patients with potentially resectable tumors.
Journal ArticleDOI
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.
Karen Becker,James Mueller,Christoph Schulmacher,Katja Ott,Ulrich Fink,Raymonde Busch,K. Böttcher,J. Rüdiger Siewert,Heinz Höfler +8 more
TL;DR: The authors performed the current study to determine which histomorphologic features are correlated with patient prognosis after chemotherapy, and which are not.
Journal ArticleDOI
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Barbara Eichhorst,Raymonde Busch,Georg Hopfinger,Rita Pasold,Manfred Hensel,Cordelia Steinbrecher,Siegfried Siehl,Ulrich Jäger,Manuela Bergmann,Stephan Stilgenbauer,Carmen D. Schweighofer,Clemens M. Wendtner,Hartmut Döhner,Günter Brittinger,Bertold Emmerich,Michael Hallek +15 more
TL;DR: First-line treatment with FC increases the response rates and the treatment-free interval in younger patients with advanced CLL and no difference in median overall survival has been observed.